July 5, 2013—The head of a patient group that has been critical of the 340B drug discount program told a House health subcommittee member last week he was correct to understand that hospitals leverage their 340B savings to buy competing cancer clinics.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)